Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab.
Br J Haematol
; 204(5): 1994-1998, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38168722
ABSTRACT
Pregnancy is a potential trigger of acute thrombotic thrombocytopenic purpura (TTP). The management of pregnancy-associated immune-mediated TTP (iTTP) can be challenging, especially when it is refractory to standard treatment. Caplacizumab, a nanobody to von Willebrand factor (VWF) blocking its A1 domain, is a valuable new therapeutic option. Its use is, however, not approved during pregnancy and breastfeeding. We describe the successful off-label administration of caplacizumab during pregnancy and delivery in a patient with refractory iTTP. The favourable outcome without significant thrombotic or haemorrhagic complications indicates that caplacizumab may be an effective and safe treatment option in refractory iTTP during pregnancy.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Complicaciones Hematológicas del Embarazo
/
Púrpura Trombocitopénica Trombótica
/
Anticuerpos de Dominio Único
Límite:
Adult
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Año:
2024
Tipo del documento:
Article